Overview

Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Primary objective: - To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria. Secondary objectives: - To determine how well irbesartan 300mg is tolerated versus 150mg - To determine the percentage of patients reaching the blood pressure target of 130/80 mmHg
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Collaborator:
Bristol-Myers Squibb
Treatments:
Irbesartan